Intech Investment Management LLC Buys 4,448 Shares of Medpace Holdings, Inc. $MEDP

by · The Markets Daily

Intech Investment Management LLC lifted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 31.9% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 18,395 shares of the company’s stock after buying an additional 4,448 shares during the period. Intech Investment Management LLC’s holdings in Medpace were worth $9,458,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Fifth Third Wealth Advisors LLC increased its stake in Medpace by 2.6% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock worth $379,000 after purchasing an additional 19 shares during the period. HighPoint Advisor Group LLC grew its holdings in shares of Medpace by 2.8% in the third quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock worth $416,000 after purchasing an additional 22 shares during the last quarter. Portside Wealth Group LLC grew its holdings in shares of Medpace by 2.5% in the second quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock worth $342,000 after purchasing an additional 27 shares during the last quarter. Whittier Trust Co. of Nevada Inc. increased its stake in shares of Medpace by 35.1% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock worth $55,000 after buying an additional 27 shares during the period. Finally, M&T Bank Corp raised its holdings in Medpace by 3.4% during the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after buying an additional 31 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Medpace

In other Medpace news, CEO August J. Troendle sold 23,178 shares of the stock in a transaction on Monday, December 1st. The stock was sold at an average price of $593.25, for a total value of $13,750,348.50. Following the completion of the transaction, the chief executive officer owned 652,550 shares in the company, valued at approximately $387,125,287.50. This represents a 3.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 20.30% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on MEDP. Wall Street Zen raised shares of Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a report on Wednesday, January 28th. Mizuho set a $582.00 price target on Medpace in a report on Wednesday, February 11th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Medpace in a research report on Wednesday, February 11th. Finally, Barclays cut their price objective on Medpace from $525.00 to $500.00 and set an “underweight” rating on the stock in a research report on Wednesday, February 11th. Four equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Medpace currently has an average rating of “Hold” and a consensus target price of $483.45.

Read Our Latest Report on Medpace

Medpace Price Performance

Shares of MEDP opened at $447.09 on Friday. The company has a 50-day simple moving average of $546.75 and a two-hundred day simple moving average of $538.26. The firm has a market capitalization of $12.69 billion, a PE ratio of 29.22, a price-to-earnings-growth ratio of 2.10 and a beta of 1.42. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $628.92.

Medpace (NASDAQ:MEDP – Get Free Report) last announced its earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.49. The firm had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business’s revenue was up 32.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Profile

(Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Featured Articles

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).